scholarly journals Relative effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of localised prostate cancer: a systematic review and mixed treatment comparison meta-analysis

2013 ◽  
Vol 112 (6) ◽  
pp. 798-812 ◽  
Author(s):  
Clare Robertson ◽  
Andrew Close ◽  
Cynthia Fraser ◽  
Tara Gurung ◽  
Xueli Jia ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Radical Prostatectomy ◽  
Meta Analysis ◽  
Relative Effectiveness ◽  
Mixed Treatment Comparison ◽  
Robot Assisted ◽  
Treatment Comparison ◽  
Open Radical Prostatectomy ◽  
Mixed Treatment

scholarly journals Comparison of Robot-Assisted Radical Prostatectomy and Open Radical Prostatectomy Outcomes: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 57 (5) ◽  
pp. 1165 ◽  
Author(s):  
Hyun-Ju Seo ◽  
Na Rae Lee ◽  
Soo Kyung Son ◽  
Dae Keun Kim ◽  
Koon Ho Rha ◽  
...  
Keyword(s):  
Systematic Review ◽  
Radical Prostatectomy ◽  
Meta Analysis ◽  
Robot Assisted ◽  
Open Radical Prostatectomy

scholarly journals Comparing Urinary and Sexual Complications of Robot-Assisted Radical Prostatectomy and Laparoscopic Radical Prostatectomy in Prostate Cancer: a Systematic Review and Meta-Analysis Protocol

2021 ◽  
Author(s):  
Afshin Heidari ◽  
◽  
Aida Kazemi ◽  
Parisa Najjari ◽  
Kamran Dalvandi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Radical Prostatectomy ◽  
Meta Analysis ◽  
Prostate Gland ◽  
Laparoscopic Radical Prostatectomy ◽  
Robot Assisted ◽  
Conventional Laparoscopic ◽  
Review Question ◽  
Analysis Protocol

Review question / Objective: The aims of this study are: 1. To compare urinary complications of robot-assisted radical prostatectomy(RARP) and laparoscopic radical prostatectomy(LRP) in patients with prostate cancer; 2. To compare sexual complications of RARP and LRP in patients with prostate cancer. Condition being studied: Prostate cancer is one of the most prevalent types of cancer; according to 2018 statistics, prostate cancer was responsible for 7.1% of all cancer in men. The primary intervention in such patients is radical prostatectomy surgery (RP), which could be performed in different methods in patients that cancer has not spread beyond the prostate gland or has not spread much. One of the most common types of RP is laparoscopic radical prostatectomy. There are several techniques for performing RP; two are Conventional Laparoscopic Radical Prostatectomy (LRP) and Robot-Assisted Radical Prostatectomy (RARP). Sexual and urinary difficulties can occur in prostate cancer patients due to cancer itself or the treatment. Like any treatment option and surgery, radical prostatectomy can carry risks, like urinary(e.g., incontinency) and sexual complications(e.g., Impotence). In this review, we compared urinary and sexual complications of LRP and RARP.

Comparative Efficacy of First Line Treatment of Chronic Myeloid Leukaemia (CML): A Systematic Review and Meta-Analysis.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3436-3436 ◽  
Author(s):  
Stuart Mealing ◽  
Leticia Barcena ◽  
Neil Hawkins ◽  
James Clark ◽  
Catherine Davis
Keyword(s):  
Systematic Review ◽  
Standard Dose ◽  
Meta Analysis ◽  
Mixed Treatment Comparison ◽  
Newly Diagnosed ◽  
First Line ◽  
Treatment Comparison ◽  
2Nd Generation ◽  
Mixed Treatment ◽  
Better Than

Abstract Abstract 3436 Introduction: Historically, interferon-alpha, hydroxyurea or chemotherapy were used as first line therapy for individuals newly diagnosed with CML. Current practice, however, recommends that tyrosine-kinase inhibitors (TKIs) be used in this patient group, with imatinib (1st generation TKI) being the current standard of care. Recent publications provide data from randomized clinical trials on 2nd generation TKIs (dasatinib and nilotinib) in the first-line setting. In the absence of randomized head to head evidence for all three TKI's, a Bayesian mixed treatment comparison meta-analysis provides a means of indirectly estimating the treatment effect of one intervention relative to another. Methods: A systematic review identified RCTs that reported or summarized efficacy data for any of the treatments of interest in treatment-naive CML patients. In order to maximise the evidence network, RCT's of non-TKI's were also included in the review. Where reported, data was extracted for molecular, hematological and cytogenic response at three montly intervals. In addition, safety and progression free and overall survival data was extracted for all reported timepoints. Extracted data was analyzed in a Bayesian mixed treatment comparison using a fixed-effects model. The outputs from all analyses were expressed as odds ratios with Imatinib 400mg SID used as the baseline intervention in all analyses. Results: Overall, 44 articles arising from 19 distinct clinical trials were included in the review. The results for complete cytogenetic response (CCyR) at twelve months (expressed as both response probabilities and odds ratios) are presented in table 1. High dose imatinib performed no better than standard dose imatinib. However, response with both 2nd generation TKIs was significantly better than with standard dose imatinib with the effect size being doubled on all endpoints. Head to head results for nilotinib and dasatinib showed no statistically significant differences (p=0.05) between the two products on all endpoints (see table 2). Conclusions: Compared to Imatinib, the use of 2nd generation TKI's for the treatment of newly diagnosed CML results in a significant improvement in complete cytogenic response. However, the current evidence base is not rich enough to distinguish between the two 2nd generation TKIs either in terms of response or progression free survival. The analyses presented will be strengthened by the inclusion of additional RCT data that may become available in the future. Disclosures: Mealing: Oxford Outcomes: Employment. Barcena:Oxford Outcomes: Employment. Hawkins:Oxford Outcomes: Employment. Clark:Oxford Outcomes: Employment. Davis:Bristol Myers-Squibb: Employment.

Sign in / Sign up

Export Citation Format

Share Document